Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Go back to Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
(NASDAQ: FULC) Delayed: 3.76 -0.01 (0.27%)
Previous Close $3.77    52 Week High
Open $3.77    52 Week Low
Day High $3.81    P/E N/A 
Day Low $3.76    EPS
Volume 3,655,192